Management of Behçet disease: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease

Annals of the Rheumatic Diseases

Volumn 68, Issue 10, 2009, Pages 1528-1534

  Hatemi, G ^a   Silman, A ^b   Bang, D ^c   Bodaghi, B ^d   Chamberlain, A M ^e   Gul, A ^f   Houman, M H ^g   Kotter I ^h   Olivieri, I ⁱ   Salvarani, C ^j   Sfikakis, P P ^k   Siva, A ^l   Stanford, M R ^m   Stubiger N ^h   Yurdakul, S ^a   Yazici, H ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Yonsei University   (South Korea)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f ISTANBUL UNIVERSITY   (Turkey)

^g LA RABTA HOSPITAL   (Tunisia)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ SAN CARLO HOSPITAL   (Italy)

^j Athens University ^*  (Italy)

^k UNIVERSITY OF ATHENS   (Greece)

^l ISTANBUL UNIVERSITY   (Turkey)

^m KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACICLOVIR; ALPHA INTERFERON; ALPHA2C INTERFERON; AZAPROPAZONE; AZATHIOPRINE; AZITHROMYCIN; BENZATHINE PENICILLIN; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; ETANERCEPT; INDOMETACIN; INFLIXIMAB; LEVAMISOLE; METHOTREXATE; METHYLPREDNISOLONE ACETATE; MINOCYCLINE; OXAPROZIN; PLACEBO; PREDNISOLONE; REBAMIPIDE; SUCRALFATE; TACROLIMUS; THALIDOMIDE; TRANSFER FACTOR; ZINC SULFATE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AZOOSPERMIA; BEHCET DISEASE; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEMORRHAGIC CYSTITIS; HUMAN; HYDROGEL; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERURICEMIA; INJECTION SITE ULCER; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROTOXICITY; PARESTHESIA; POLYNEUROPATHY; PRIORITY JOURNAL; PULMONARY ARTERY ANEURYSM; REMISSION; REPEATED DRUG DOSE; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VOMITING;

ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349378464     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.087957     Document Type: Article

References (94)

1. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet's disease. Ann Rheum Dis 2008;67:1656-1662
2. Osiri M, Suarez-Almazor ME, Wells GA, et al. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 2003;62:316-321 (Pubitemid 36363436)
3. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990;322:281-285 (Pubitemid 20046329)
4. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-774 (Pubitemid 127744665)
5. Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum 2000;43:692-700.
6. Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon a combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J 2002;4(Suppl):928-930 (Pubitemid 35291273)
7. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992;76:241-243
8. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 1988;20(Suppl 4):136-143 (Pubitemid 18158695)
9. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989;1:1093-1096 (Pubitemid 19128039)
10. Cantini F, Salvarani C, Niccoli L, et al. Treatment of thrombophlebitis of Behcet's disease with low dose cyclosporin A. Clin Exp Rheumatol 1999;17:391-392 (Pubitemid 29265696)
11. Atmaca LS, Batioglu F. The efficacy of cyclosporin-A in the treatment of Behcet's disease. Ophthalmic Surg 1994;25:321-327 (Pubitemid 24149976)
12. Chavis PS, Antonios SR, Tabbara KF. Cyclosporine effects on optic nerve and retinal vasculitis in Behcet's disease. Doc Ophthalmol 1992;80:133-142
13. Ermakova NA. Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Behcet's disease. Adv Exp Med Biol 2003;528:563-565
14. Fujino Y, Joko S, Masuda K, et al. Ciclosporin microemulsion preconcentrate treatment of patients with Behcet's disease. Jpn J Ophthalmol 1999;43:318-326 (Pubitemid 29329393)
15. Hayasaka S, Kawamoto K, Noda S, et al. Visual prognosis in patients with Behcet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Ophthalmologica 1994;208:210-213 (Pubitemid 24259789)
16. Ozdal PC, Ortac S, Taskintuna I, et al. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 2002;105:301-312 (Pubitemid 36018751)
17. Pacor ML, Biasi D, Lunardi C, et al. Cyclosporin in Behcet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol 1994;13:224-227 (Pubitemid 24199147)
18. Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Behcet's disease. J Ocul Pharmacol 1994;10:553-560 (Pubitemid 24321154)
19. Sullu Y, Oge I, Erkan D, et al. Cyclosporin-A therapy in severe uveitis of Behcet's disease. Acta Ophthalmol Scand 1998;76:96-99 (Pubitemid 28120607)
20. Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994;118:39-45.
21. Nussenblatt RB, Palestine AG, Chan CC, et al. Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 1985;28:671-679
22. Muftuoglu AU, Pazarli H, Yurdakul S, et al. Short term cyclosporin A treatment of Behcet's disease. Br J Ophthalmol 1987;71:387-390 (Pubitemid 17072286)
23. Wechsler B, Mertani EB, le Hoang P, et al. Cyclosporin A is effective, but not safe, in the management of Behcet's disease. Arthritis Rheum 1986;29:574-575 (Pubitemid 16118710)
24. Diaz-Llopis M, Cervera M, Menezo JL. Cyclosporin A treatment of Behcet's disease: a long-term study. Curr Eye Res 1990;9(Suppl):17-23. (Pubitemid 20295595)
25. Binder AI, Graham EM, Sanders MD, et al. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol 1987;26:285-291 (Pubitemid 17103851)
26. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-589 (Pubitemid 30191596)
27. Kotter I, Gunaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behcet's disease under cyclosporin A (CSA) than under other medications - results of a retrospective analysis of 117 cases. Clin Rheumatol 2006;25:482-486 (Pubitemid 44137619)
28. Kato Y, Numaga J, Kato S, et al. Central nervous system symptoms in a population of Behcet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001;29:335-336 (Pubitemid 33039850)
29. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon a-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-471 (Pubitemid 34290024)
30. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004;33:311-319 (Pubitemid 38496040)
31. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon α-2a for the treatment of with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-431 (Pubitemid 36399030)
32. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon α-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 2000;8:293-301. (Pubitemid 32174750)
33. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-339 (Pubitemid 46586530)
34. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-a therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:1692-1695 (Pubitemid 44830831)
35. Krause L, Turnbull JR, Torun N, et al. Interferon α-2a in the treatment of ocular Adamantiades-Behcet's disease. Adv Exp Med Biol 2003;528:511-519
36. Calguneri M, Ozturk MA, Ertenli I, et al. Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study. Ann Rheum Dis 2003;62:492-493 (Pubitemid 36469751)
37. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behcet's disease. J Am Acad Dermatol 1994;31:617-619
38. Azizlerli G, Sarica R, Kose A, et al. Interferon α-2a in the treatment of Behcet's disease. Dermatology 1996;192:239-241
39. Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2A treatment in Behcet's disease. Dermatology 2000;201:40-43 (Pubitemid 30687527)
40. Georgiou S, Monastirli A, Pasmatzi E, et al. Efficacy and safety of systemic recombinant interferon-alpha in Behcet's disease. J Intern Med 1998;243:367-372 (Pubitemid 28255481)
41. O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behcet's disease. J Rheumatol 1998;25:1938-1944
42. Zouboulis CC, Treudler R, Orfanos CE. Adamantiades-Behcet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a. Hautarzt 1993;44:440-445
43. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-741 (Pubitemid 47061701)
44. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sightthreatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004;140:404-406 (Pubitemid 38268925)
45. Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-536
46. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol 2004;22(Suppl 34):S14-6. (Pubitemid 39359729)
47. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005;52:2478-2484 (Pubitemid 41117435)
48. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-1368 (Pubitemid 38879203)
49. Abu El-Asrar AM, Abboud EB, Aldibhi H, et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease. Int Ophthalmol 2005;26:83-150 (Pubitemid 44781873)
50. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105. (Pubitemid 40092599)
51. Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behcet's syndrome: a report of 24 cases. Br J Rheumatol 1994;33:48-51. (Pubitemid 24042036)
52. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004;117:867-870 (Pubitemid 39602798)
53. Du LT, Fain O, Wechsler B, et al. Value of ''bolus'' cyclophosphamide injections in Behcet's disease. Experience of cases. Presse Med 1990;19:1355-1358
54. Hamza M, Meddeb S, Mili I, et al. Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet's disease. Preliminary results with the use of new criteria of evaluation. Ann Med Interne (Paris) 1992;143:438-441
55. Oniki S, Kurakazu K, Kawata K. Treatment of Behcet's disease with cyclophosphamide. Nippon Ganka Gakkai Zasshi 1973;77:508-515
56. Kazokoglu H, Saatci O, Cuhadaroglu H, et al. Long-term effects of cyclophosphamide and colchicine treatment in Behcet's disease. Ann Ophthalmol 1991;23:148-151
57. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980;65:399-402. (Pubitemid 11254772)
58. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001;44:2686-2692 (Pubitemid 33049346)
59. Mumcu G, Ergun T, Elbir Y, et al. Clinical and immunological effects of azithromycin in Behcet's disease. J Oral Pathol Med 2005;34:13-16 (Pubitemid 40142924)
60. Mizushima Y, Matsumura N, Mori M, et al. Colchicine in Behcet's disease. Lancet 1977;2:1037.
61. Al-Waiz MM, Sharquie KE, A-Qaissi MH, et al. Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. Dermatol Online J 2005;11:3.
62. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-450
63. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-832
64. Saylan T, Saltik I. Thalidomide in the treatment of Behcet's syndrome. Arch Dermatol 1982;118:536.
65. Hamza MH. Treatment of Behcet's disease with thalidomide. Clin Rheumatol 1986;5:365-371
66. Calguneri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum 1996;39:2062-2065 (Pubitemid 27009075)
67. Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology 1996;192:125-128 (Pubitemid 26072443)
68. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997;38:444-454 (Pubitemid 28117055)
69. Mumcu G, Ergun T, Elbir Y, et al. Clinical and immunological effects of azithromycin in Behcet's disease. J Oral Pathol Med 2005;34:13-16 (Pubitemid 40142924)
70. Hamza M, Ayed K, Ben Ayed H. Treatment of Behcet's disease with levamisole. Arthritis Rheum 1982;25:714-715
71. Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome: a randomized double-blind trial. Br J Rheumatol 1988;27:300-302
72. Moral F, Hamuryudan V, Yurdakul S, et al. Inefficacy of azapropazone in the acute arthritis of Behcet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995;13:493-495
73. Simsek H, Dundar S, Telatar H. Treatment of Behcet disease with indomethacin. Int J Dermatol 1991;30:54-57
74. Takeuchi A, Mori M, Hashimoto A, et al. Efficacy of oxaprozin in the treatment of articular symptoms of Behcet's disease. Clin Rheumatol 1984;3:397-399 (Pubitemid 15072125)
75. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 2006;45:348-352 (Pubitemid 43372853)
76. Cashay AR, Rahimi A, Chams H, et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet's disease. Eye 2003;17:762-766 (Pubitemid 37120971)
77. Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet's disease. Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc 1991;23:3343-3346
78. Sakane T, Mochizuki M, Inaba G, et al. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behcet's disease and allied conditions. Ryumachi 1995;35:802-813
79. Davatchi F, Shahram F, Chams H, et al. High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol 2003;528:579-584
80. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003;4:19-28. (Pubitemid 37062641)
81. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a doubleblind, placebo-controlled, cross-over study. J Dermatol 2002;29:267-279
82. Denman AM, Hollingworth P, Webster ADB, et al. Failure of transfor factor in the treatment of Behçet's syndrome: a double blind trial. In: Lehner T, Barnes CG, eds. Behçet's syndrome. London, UK: Academic Press, 1979: 227-289
83. Sharquie KE, Najim RA, Al-Dori WS, et al. Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study. J Dermatol 2006;33:541-546
84. Elliott JH, Ballinger WH. Behcet's syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc 1984;82:264-281
85. Mamo JG. Treatment of Behcet disease with chlorambucil. A follow-up report. Arch Ophthalmol 1976;94:580-583
86. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001;9:219-229 (Pubitemid 34286623)
87. Tabbara KF. Chlorambucil in Behcet's disease. A reappraisal. Ophthalmology 1983;90:906-908
88. Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 1990;74:353-357 (Pubitemid 20191168)
89. O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984;76:75-84. (Pubitemid 14216363)
90. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003;528:575-578
91. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998;159:181-185 (Pubitemid 28384527)
92. Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999;135:529-532 (Pubitemid 29222295)
93. Hamuryudan V, Yurdakul S, Rosenkaimer F, et al. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet's syndrome: a randomized, double blind trial. Br J Rheumatol 1991;30:395-396
94. Ergun T, Gurbuz O, Yurdakul S, et al. Topical cyclosporine-A for treatment of oral ulcers of Behcet's syndrome. Int J Dermatol 1997;36:720. (Pubitemid 27452162)